<h1>Pharma company welcomes GST cuts on medicines, devices and diagnostics; pledges price recalibration and stakeholder coordination</h1> A pharmaceutical company welcomed recent GST Council reforms that lower tax rates on medicines, life-saving drugs, medical devices, diagnostic kits and exempt individual health insurance, anticipating reduced treatment costs and wider insurance uptake. The company stated it will recalibrate pricing to reflect revised GST rates and coordinate with healthcare professionals, distributors and retailers to implement changes. The measures are presented as likely to improve access to innovative therapies, support treatment adherence, and foster industry growth; the company committed to passing benefits to consumers and collaborating with stakeholders to maximize impact across human and animal health.